Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
750 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-11-01
Study Completion Date
2028-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with an anti-amyloid monoclonal antibody (mAb), in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.
This platform trial allows for the simultaneous testing of multiple tau therapies under a shared master protocol. This means that multiple investigational products will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen.
The main questions the platform trial aims to answer are:
* Does any tau-directed therapy, alone or in combination with an anti-amyloid mAb, reduce brain tau deposition more than an anti-amyloid mAb, alone?
* Does any tau-directed therapy, alone or in combination with an anti-amyloid mAb, slow disease progression based on fluid biomarkers, imaging, or clinical measures?
Participants will:
* Be randomized to a treatment regimens, each containing different tau therapies. The exact number of treatment regimens that will active at the time of screening will change over time.
* Receive an anti-amyloid mAb or placebo for 6 months, followed by 24 months of tau therapy alone or in combination with an anti-amyloid mAb.
* Undergo regular cognitive testing, brain scans (MRI/PET), and biomarker assessments over 30 months
Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to one of three arms: (1) tau therapy alone, (2) a combination of an anti-amyloid mAb and tau therapy, or (3) an anti-amyloid mAb alone.
New regimens will be continuously added as new investigational products become available. The Alzheimer's Tau Platform Trial will enroll additional participants as each new regimen becomes available.
ATP is expected to launch with two regimens:
* Regimen A: AADvac1
* Regimen B: Tau2
This platform trial allows for the simultaneous testing of multiple tau therapies under a shared master protocol. This means that multiple investigational products will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen.
The main questions the platform trial aims to answer are:
* Does any tau-directed therapy, alone or in combination with an anti-amyloid mAb, reduce brain tau deposition more than an anti-amyloid mAb, alone?
* Does any tau-directed therapy, alone or in combination with an anti-amyloid mAb, slow disease progression based on fluid biomarkers, imaging, or clinical measures?
Participants will:
* Be randomized to a treatment regimens, each containing different tau therapies. The exact number of treatment regimens that will active at the time of screening will change over time.
* Receive an anti-amyloid mAb or placebo for 6 months, followed by 24 months of tau therapy alone or in combination with an anti-amyloid mAb.
* Undergo regular cognitive testing, brain scans (MRI/PET), and biomarker assessments over 30 months
Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to one of three arms: (1) tau therapy alone, (2) a combination of an anti-amyloid mAb and tau therapy, or (3) an anti-amyloid mAb alone.
New regimens will be continuously added as new investigational products become available. The Alzheimer's Tau Platform Trial will enroll additional participants as each new regimen becomes available.
ATP is expected to launch with two regimens:
* Regimen A: AADvac1
* Regimen B: Tau2
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alzheimer's Tau Platform: Regimen A - AADvac1
NCT07167966
Preclinical Alzheimer's Disease
Prodromal Alzheimer's Disease
Alzheimer Disease
NOT_YET_RECRUITING
PHASE2
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
NCT00736775
Alzheimer's Disease
COMPLETED
PHASE1
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
NCT01689246
Alzheimer's Disease
COMPLETED
PHASE3
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547
Alzheimer Disease
Dementia
COMPLETED
PHASE3
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
NCT04191486
Mild Cognitive Impairment
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Preclinical Alzheimer's Disease
Alzheimer Disease
Prodromal Alzheimer's Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
As new investigational products become available, additional regimens will be added to the Alzheimer's Tau Platform trial.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regimen A: AADvac1
Participants are randomized to receive either AADvac1, a tau directed monotherapy, combination AADvac1 with an anti-amyloid monoclonal antibody (mAb), or an anti-amyloid mAb alone (active control)
Group Type
EXPERIMENTAL
AADvac1
Intervention Type
DRUG
AADvac1 tau directed therapy
Regimen B: Tau2
Participants are randomized to receive either Tau2 directed monotherapy, combination Tau2 directed therapy with an anti-amyloid monoclonal antibody (mAb), or an anti-amyloid mAb alone (active control)
Group Type
EXPERIMENTAL
Tau2
Intervention Type
DRUG
Tau2 directed therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AADvac1
AADvac1 tau directed therapy
Intervention Type
DRUG
Tau2
Tau2 directed therapy
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Documentation of the participant's informed consent to study procedures (including APOE genotyping).
2. Ages 50-80 years (inclusive). Participants between the ages of 50 and 60 (inclusive) must be mildly impaired at screening (global CDR=0.5 and maximum CDR-SB \<1.5
3. Cognitively unimpaired (preclinical AD with a global CDR=0) or mildly impaired (prodromal AD with a global CDR=0.5 and maximum CDR-SB \<1.5).
4. MMSE score at screening of 20-30 (inclusive) with educational adjustments:
1. If \<12 years of education, MMSE required to be \>20.
2. If 13 to 15 years (inclusive) of education, MMSE required to be \>22.
3. If \>16 years of education, MMSE required to be \>24.
5. Plasma biomarker result at screening that demonstrate the presence of amyloid pathology, consistent with preclinical-prodromal AD.
6. Elevated brain tau on PET (MTL or NEO tau SUVr \>1.2) at screening.
7. Elevated brain amyloid on PET (centiloids \> 40) at screening.
8. Stable doses of permitted medications as described per protocol for a minimum of 30 days prior to screening.
9. Resides at home or in the community (assisted living acceptable).
10. In the opinion of the site PI, has a study partner able and willing to provide accurate information (including clinical symptoms and medical history) about the participant and participate in study visits and informant-based assessments (usually requires at least 5 hours of contact per week) for the duration of the study.
11. As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.
12. Must complete all screening evaluations as outlined per protocol.
2. Ages 50-80 years (inclusive). Participants between the ages of 50 and 60 (inclusive) must be mildly impaired at screening (global CDR=0.5 and maximum CDR-SB \<1.5
3. Cognitively unimpaired (preclinical AD with a global CDR=0) or mildly impaired (prodromal AD with a global CDR=0.5 and maximum CDR-SB \<1.5).
4. MMSE score at screening of 20-30 (inclusive) with educational adjustments:
1. If \<12 years of education, MMSE required to be \>20.
2. If 13 to 15 years (inclusive) of education, MMSE required to be \>22.
3. If \>16 years of education, MMSE required to be \>24.
5. Plasma biomarker result at screening that demonstrate the presence of amyloid pathology, consistent with preclinical-prodromal AD.
6. Elevated brain tau on PET (MTL or NEO tau SUVr \>1.2) at screening.
7. Elevated brain amyloid on PET (centiloids \> 40) at screening.
8. Stable doses of permitted medications as described per protocol for a minimum of 30 days prior to screening.
9. Resides at home or in the community (assisted living acceptable).
10. In the opinion of the site PI, has a study partner able and willing to provide accurate information (including clinical symptoms and medical history) about the participant and participate in study visits and informant-based assessments (usually requires at least 5 hours of contact per week) for the duration of the study.
11. As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.
12. Must complete all screening evaluations as outlined per protocol.
Exclusion Criteria
1. Females who are lactating or pregnant (as documented by a urine pregnancy test) during screening, or plan to become pregnant during the study.
2. Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and/or are not willing to use highly effective method of contraception for the duration of their participation in the study. Males who are sexually active with a female of childbearing potential and do not agree to use barrier methods of contraception (condoms with spermicide) during the trial and for 6 months after the last dose of study drug unless the female is using a highly effective method of contraception.
3. Lacks good venous access such that multiple blood draws would be precluded.
4. Weighs less than 40kg, or more than 136kg at screening.
5. Suspected or known allergic reactions, adverse reactions, or hypersensitivity to any components of the study intervention for any of the available regimen.
6. Previous treatment with the study intervention from any available regimen unless it can be confirmed the participant received placebo in the previous study.
7. Prior or current treatment with a prohibited medication as described per protocol.
8. Enrollment in another investigational study as described per protocol. Participants enrolled in an observational study may be permitted with Medical Monitor review and approval.
9. Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and/or severe claustrophobia.
10. MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or showing more than four (4) cerebral microhemorrhages (defined as 10 mm or less at the greatest diameter); evidence of a prior or current macrohemorrhage (greater than 10 mm at greatest diameter, also referred to as intracerebral hemorrhage \>1 cm within this protocol); cerebral contusion; encephalomalacia; aneurysms greater than 6 mm, or any aneurysms that have not been stable in size for the past 2 years; vascular malformations that are at high risk for hemorrhage; infectious lesions; evidence of multiple lacunar infarcts (that in the opinion of the investigator, may impact cognition); stroke involving a major vascular territory; severe small vessel disease; severe diffuse white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and less than 1 cm at their greatest diameter need not be exclusionary).
11. Contraindications to tau and/or amyloid PET scan imaging and/or use of MK6240 and/or 18F-NAV-4694 (flutafuranol).
12. For participants undergoing an LP as part of the optional longitudinal CSF biomarker sub-study, contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) \>1.4 or other coagulopathy; platelet count of \<120,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of LP NOTE: low dose aspirin is permitted; degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
13. Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., moderate and/or severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per the site PI's judgement.
14. History of severe allergic reaction (e.g., anaphylaxis) including, but not limited to: severe allergic reaction to previous vaccines, foods, and/or medications.
15. Hospitalization within 30 days prior to screening or baseline.
16. Clinically significant infections or major surgical operation within 3 months prior to screening.
17. History of chronic or recurrent infections judged to be clinically significant by the site PI and which would potentially hamper the evaluation of efficacy and safety assessments.
18. Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, or significant coronary artery disease.
19. History of cancer within the past 5 years other than treated squamous cell carcinoma, basal cell carcinoma and melanoma in-situ, in-situ prostate cancer, or in-situ breast cancer, which have been fully removed and are considered cured.
20. History of inflammatory neurological disorders.
21. History or presence of immunological or inflammatory conditions, including neurological disorders, judged to be clinically significant by the site PI.
22. History of meningitis or meningoencephalitis.
23. History of moderate or severe traumatic brain injury.
24. History or presence of uncontrolled seizures. If history of seizures, they must be well controlled with no occurrence of seizures in the 2 years prior to study screening. The use of antiepileptic medications is permitted (see section 6.5.2).
25. Concomitant or past history of psychiatric or neurologic disorder other than those considered to be related to AD (e.g., head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks, hemorrhagic and/or non-hemorrhagic stroke).
26. DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
27. Significant risk of suicide defined, using the C-SSRS, as the participant answering "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior within the past 6 months.
28. Clinically significant abnormal vital signs including sustained sitting blood pressure \>160/90 mm Hg.
29. Participants with diabetes mellitus with hemoglobin A1c (HbA1c) levels of \>7.5%.
30. In the opinion of the site PI, clinically significant deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, including, but not limited to:
1. hematocrit less than 35% for those with male biological sex and less than 32% for those with female biological sex.
2. absolute neutrophil cell count \<1500/uL (with the exception of a chronic benign neutropenia).
3. absolute lymphocyte count \<900/uL.
4. platelet cell count of \<100,000/uL.
5. INR \>1.4 or other coagulopathy, confirmed by repeat (not applicable for participants on anticoagulation).
31. Participants with a known history of human immunodeficiency virus infection (HIV-1 and 2).
32. Participants with known history of acute/chronic hepatitis B or C.
33. Any other clinically significant, advanced, or unstable disease that may interfere with outcome evaluations, such as:
1. Chronic liver disease.
2. Respiratory insufficiency.
3. Renal insufficiency defined as estimated glomerular filtration rate (eGFR) \<50 mL/min based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
4. Bradycardia (\<50/min) or tachycardia (\>100/min). Bradycardia \>40/min and \<50/min may be permitted with review and approval by the Medical Monitor.
34. Clinically significant arrhythmias or other clinically significant abnormalities on ECG at screening (minor abnormalities documented as clinically insignificant by the site PI are allowed).
35. Any condition, which in the opinion of the site PI, Coordinating Center, or Project Lead/Protocol PI, makes the participant unsuitable for inclusion.
2. Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and/or are not willing to use highly effective method of contraception for the duration of their participation in the study. Males who are sexually active with a female of childbearing potential and do not agree to use barrier methods of contraception (condoms with spermicide) during the trial and for 6 months after the last dose of study drug unless the female is using a highly effective method of contraception.
3. Lacks good venous access such that multiple blood draws would be precluded.
4. Weighs less than 40kg, or more than 136kg at screening.
5. Suspected or known allergic reactions, adverse reactions, or hypersensitivity to any components of the study intervention for any of the available regimen.
6. Previous treatment with the study intervention from any available regimen unless it can be confirmed the participant received placebo in the previous study.
7. Prior or current treatment with a prohibited medication as described per protocol.
8. Enrollment in another investigational study as described per protocol. Participants enrolled in an observational study may be permitted with Medical Monitor review and approval.
9. Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and/or severe claustrophobia.
10. MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or showing more than four (4) cerebral microhemorrhages (defined as 10 mm or less at the greatest diameter); evidence of a prior or current macrohemorrhage (greater than 10 mm at greatest diameter, also referred to as intracerebral hemorrhage \>1 cm within this protocol); cerebral contusion; encephalomalacia; aneurysms greater than 6 mm, or any aneurysms that have not been stable in size for the past 2 years; vascular malformations that are at high risk for hemorrhage; infectious lesions; evidence of multiple lacunar infarcts (that in the opinion of the investigator, may impact cognition); stroke involving a major vascular territory; severe small vessel disease; severe diffuse white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and less than 1 cm at their greatest diameter need not be exclusionary).
11. Contraindications to tau and/or amyloid PET scan imaging and/or use of MK6240 and/or 18F-NAV-4694 (flutafuranol).
12. For participants undergoing an LP as part of the optional longitudinal CSF biomarker sub-study, contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) \>1.4 or other coagulopathy; platelet count of \<120,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of LP NOTE: low dose aspirin is permitted; degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
13. Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., moderate and/or severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per the site PI's judgement.
14. History of severe allergic reaction (e.g., anaphylaxis) including, but not limited to: severe allergic reaction to previous vaccines, foods, and/or medications.
15. Hospitalization within 30 days prior to screening or baseline.
16. Clinically significant infections or major surgical operation within 3 months prior to screening.
17. History of chronic or recurrent infections judged to be clinically significant by the site PI and which would potentially hamper the evaluation of efficacy and safety assessments.
18. Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, or significant coronary artery disease.
19. History of cancer within the past 5 years other than treated squamous cell carcinoma, basal cell carcinoma and melanoma in-situ, in-situ prostate cancer, or in-situ breast cancer, which have been fully removed and are considered cured.
20. History of inflammatory neurological disorders.
21. History or presence of immunological or inflammatory conditions, including neurological disorders, judged to be clinically significant by the site PI.
22. History of meningitis or meningoencephalitis.
23. History of moderate or severe traumatic brain injury.
24. History or presence of uncontrolled seizures. If history of seizures, they must be well controlled with no occurrence of seizures in the 2 years prior to study screening. The use of antiepileptic medications is permitted (see section 6.5.2).
25. Concomitant or past history of psychiatric or neurologic disorder other than those considered to be related to AD (e.g., head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks, hemorrhagic and/or non-hemorrhagic stroke).
26. DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
27. Significant risk of suicide defined, using the C-SSRS, as the participant answering "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior within the past 6 months.
28. Clinically significant abnormal vital signs including sustained sitting blood pressure \>160/90 mm Hg.
29. Participants with diabetes mellitus with hemoglobin A1c (HbA1c) levels of \>7.5%.
30. In the opinion of the site PI, clinically significant deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, including, but not limited to:
1. hematocrit less than 35% for those with male biological sex and less than 32% for those with female biological sex.
2. absolute neutrophil cell count \<1500/uL (with the exception of a chronic benign neutropenia).
3. absolute lymphocyte count \<900/uL.
4. platelet cell count of \<100,000/uL.
5. INR \>1.4 or other coagulopathy, confirmed by repeat (not applicable for participants on anticoagulation).
31. Participants with a known history of human immunodeficiency virus infection (HIV-1 and 2).
32. Participants with known history of acute/chronic hepatitis B or C.
33. Any other clinically significant, advanced, or unstable disease that may interfere with outcome evaluations, such as:
1. Chronic liver disease.
2. Respiratory insufficiency.
3. Renal insufficiency defined as estimated glomerular filtration rate (eGFR) \<50 mL/min based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
4. Bradycardia (\<50/min) or tachycardia (\>100/min). Bradycardia \>40/min and \<50/min may be permitted with review and approval by the Medical Monitor.
34. Clinically significant arrhythmias or other clinically significant abnormalities on ECG at screening (minor abnormalities documented as clinically insignificant by the site PI are allowed).
35. Any condition, which in the opinion of the site PI, Coordinating Center, or Project Lead/Protocol PI, makes the participant unsuitable for inclusion.
Minimum Eligible Age
50 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Sponsor Role
collaborator
University of California, San Francisco
OTHER
Sponsor Role
collaborator
Massachusetts General Hospital
OTHER
Sponsor Role
collaborator
Alzheimer's Therapeutic Research Institute
OTHER
Sponsor Role
collaborator
Alzheimer's Clinical Trials Consortium
OTHER
Sponsor Role
collaborator
Paul S. Aisen
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul S. Aisen
Director, ATRI
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Boxer, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco (UCSF), Memory and Aging Center
Keith Johnson, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital (MGH), Harvard Medical School
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
https://www.actcinfo.org/trial/alzheimers-tau-platform-atp-clinical-trial/
ACTC Alzheimer's Tau Platform
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATRI-014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
RECRUITING
PHASE2/PHASE3
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
RECRUITING
PHASE2/PHASE3
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
NCT00566397
COMPLETED
PHASE2
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
NCT03446001
COMPLETED
PHASE3
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
NCT00722046
COMPLETED
PHASE2
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
NCT04685590
ACTIVE_NOT_RECRUITING
PHASE2
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT03131453
TERMINATED
PHASE2/PHASE3
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT02565511
TERMINATED
PHASE2/PHASE3
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
NCT03828747
COMPLETED
PHASE2
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
NCT02547818
COMPLETED
PHASE3
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
NCT01466088
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
RECRUITING
PHASE2
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
NCT04187547
WITHDRAWN
PHASE3
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572
COMPLETED
PHASE2
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
NCT01117818
COMPLETED
PHASE2
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
NCT02423200
COMPLETED
PHASE2
A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
NCT00777608
COMPLETED
PHASE1
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
COMPLETED
PHASE1
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420
COMPLETED
PHASE2
Multiple Dose Study of TRx0037
NCT01253499
COMPLETED
PHASE1
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
NCT03507790
COMPLETED
PHASE2
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
NCT06840054
NOT_YET_RECRUITING
PHASE2
ATP in Alzheimer Disease
NCT02279511
COMPLETED
PHASE2
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936
COMPLETED
PHASE2
Efficacy and Safety of MMFS in Early AD
NCT03531684
COMPLETED
PHASE2